Published in Ann Rheum Dis on November 19, 2008
Study of MRA in Patients With Rheumatoid Arthritis (RA) | NCT00144651
IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex. J Neurosci (2010) 1.52
Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS One (2015) 1.40
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther (2010) 1.38
Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant (2011) 1.37
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis (2013) 1.31
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis (2011) 1.27
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci (2012) 1.27
NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother (2010) 1.25
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Curr Rheumatol Rev (2011) 1.23
Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther (2012) 1.23
Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol (2011) 1.22
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol (2009) 1.13
Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol Pain (2012) 1.11
The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol (2010) 1.07
A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Ann Rheum Dis (2012) 1.02
Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag (2008) 1.00
Tocilizumab. MAbs (2009) 0.97
Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord (2010) 0.97
Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int (2009) 0.94
Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep (2011) 0.94
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol (2010) 0.88
Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.87
Emerging strategies and therapies for treatment of Paget's disease of bone. Drug Des Devel Ther (2011) 0.87
Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int (2011) 0.87
Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis (2014) 0.86
Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence (2013) 0.86
Advances in the treatment of rheumatoid arthritis. F1000Prime Rep (2014) 0.84
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics (2016) 0.84
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis (2013) 0.83
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther (2014) 0.82
Local action of the proinflammatory cytokines IL-1β and IL-6 on intracranial meningeal nociceptors. Cephalalgia (2011) 0.82
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Prefer Adherence (2014) 0.82
Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther (2012) 0.80
IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. J Thromb Haemost (2013) 0.80
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther (2015) 0.79
Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. Rheumatol Int (2015) 0.78
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther (2016) 0.78
Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis. Clin Rheumatol (2015) 0.78
Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis. Br J Cancer (2015) 0.77
Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Res Ther (2010) 0.77
Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease. Osteoporos Int (2012) 0.76
ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol (2009) 0.76
Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years. Biologics (2016) 0.75
Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One (2017) 0.75
Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature. Open Access Rheumatol (2013) 0.75
New and emerging therapies for the treatment of rheumatoid arthritis. Open Access Rheumatol (2010) 0.75
Interleukin 6 blockage-induced neutropenia in a patient with rheumatoid arthritis and resolved hepatitis B. Reumatologia (2016) 0.75
Herpes Zoster Meningitis Complicating Combined Tocilizumab and Cyclosporine Therapy for Adult-Onset Still's Disease. Case Rep Rheumatol (2016) 0.75
Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis. Clin Rheumatol (2016) 0.75
IL-6 blockade in chronic inflammatory diseases. Wien Med Wochenschr (2014) 0.75
Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab. Rheumatol Ther (2014) 0.75
Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy. Emerg Infect Dis (2011) 0.75
Acute Generalized Exanthematous Pustulosis due to Tocilizumab in a Rheumatoid Arthritis Patient. Case Rep Rheumatol (2012) 0.75
Anti-Arthritic Effect of Chebulanin on Collagen-Induced Arthritis in Mice. PLoS One (2015) 0.75
Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients. J Immunol Res (2015) 0.75
Tocilizumab (Actemra). Hum Vaccin Immunother (2017) 0.75
Anti-interleukin 6: first line in rheumatoid arthritis? Clin Rheumatol (2009) 0.75
[Biologics and cardiovascular risk]. Z Rheumatol (2010) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum (1995) 15.00
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest (2004) 11.05
Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med (1990) 7.49
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet (2008) 7.37
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis (2008) 6.97
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 3.92
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol (2005) 2.40
Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol (2004) 2.20
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis (2005) 1.84
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol (2003) 1.69
Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis (2000) 1.56
Toward a protein-protein interaction map of the budding yeast: A comprehensive system to examine two-hybrid interactions in all possible combinations between the yeast proteins. Proc Natl Acad Sci U S A (2000) 10.98
New procedure for DNA transfection with polycation and dimethyl sulfoxide. Mol Cell Biol (1984) 8.63
The effects of reciprocal changes in temperature on the transformed state of cells infected with a rous sarcoma virus mutant. Virology (1971) 7.83
Hd1, a major photoperiod sensitivity quantitative trait locus in rice, is closely related to the Arabidopsis flowering time gene CONSTANS. Plant Cell (2000) 6.93
A high-density rice genetic linkage map with 2275 markers using a single F2 population. Genetics (1998) 6.82
Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci (1995) 6.36
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature (1996) 5.45
Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology (1992) 5.16
A 300 kilobase interval genetic map of rice including 883 expressed sequences. Nat Genet (1994) 5.08
Recovery of avian sarcoma virus from tumors induced by transformation-defective mutants. J Exp Med (1977) 4.79
Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol Immunol (1986) 4.38
Genetic recombination with avian tumor virus. Virology (1972) 4.23
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest (1999) 3.86
The erbB gene of avian erythroblastosis virus is a member of the src gene family. Cell (1983) 3.82
Location of envelope-specific and sarcoma-specific oligonucleotides on RNA of Schmidt-Ruppin Rous sarcoma virus. Proc Natl Acad Sci U S A (1976) 3.73
Experimental transmission of Bartonella henselae by the cat flea. J Clin Microbiol (1996) 3.67
Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci U S A (1997) 3.66
Characterization of Y73, an avian sarcoma virus: a unique transforming gene and its product, a phosphopolyprotein with protein kinase activity. Proc Natl Acad Sci U S A (1980) 3.58
New antibiotics, bleomycin A and B. J Antibiot (Tokyo) (1966) 3.58
Isolation of defective mutant of avian sarcoma virus. Proc Natl Acad Sci U S A (1973) 3.38
Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci (1994) 3.36
Production of cholera-like enterotoxin by a Vibrio cholerae non-O1 strain isolated from the environment. Infect Immun (1981) 3.21
Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene (2007) 3.11
Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun (1999) 3.03
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood (1996) 2.98
Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biochemical properties of mutant TK15 and mutant-induced transformants. J Virol (1984) 2.95
Similarity among the Drosophila (6-4)photolyase, a human photolyase homolog, and the DNA photolyase-blue-light photoreceptor family. Science (1996) 2.74
Non-O1 Vibrio cholerae hemolysin: purification, partial characterization, and immunological relatedness to El Tor hemolysin. Infect Immun (1984) 2.72
The NPH4 locus encodes the auxin response factor ARF7, a conditional regulator of differential growth in aerial Arabidopsis tissue. Plant Cell (2000) 2.68
Migrastatin, a new inhibitor of tumor cell migration from Streptomyces sp. MK929-43F1. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) (2000) 2.64
Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest (1993) 2.64
Purification and some properties of a non-o1 Vibrio cholerae enterotoxin that is identical to cholera enterotoxin. Infect Immun (1983) 2.62
Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol (1995) 2.61
Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet (1982) 2.58
Purification and partial characterization of heat-stable enterotoxin of enterotoxigenic Escherichia coli. Infect Immun (1979) 2.55
Unifected avian cells contain structurally unrelated progenitors of viral sarcoma genes. Nature (1980) 2.50
Enterotoxicity of El Tor-like hemolysin of non-O1 Vibrio cholerae. Infect Immun (1987) 2.46
Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother (2001) 2.46
Ludloff's medial approach for open reduction of congenital dislocation of the hip. A 20-year follow-up. J Bone Joint Surg Br (1996) 2.45
Complete nucleotide sequences of 93-kb and 3.3-kb plasmids of an enterohemorrhagic Escherichia coli O157:H7 derived from Sakai outbreak. DNA Res (1998) 2.43
New medium for the production of cholera toxin by Vibrio cholerae O1 biotype El Tor. J Clin Microbiol (1985) 2.43
Identification of TATA-binding protein-free TAFII-containing complex subunits suggests a role in nucleosome acetylation and signal transduction. J Biol Chem (1999) 2.43
Transformation-defective mutants of Rous sarcoma virus with src gene deletions of varying length. J Virol (1977) 2.43
Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of Porphyromonas gingivalis. Construction of mutants with a combination of rgpA, rgpB, kgp, and hagA. J Biol Chem (1999) 2.39
Association of genetic variation in FTO with risk of obesity and type 2 diabetes with data from 96,551 East and South Asians. Diabetologia (2011) 2.37
Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax (2008) 2.37
RNA of replication-defective strains of Rous sarcoma virus. Proc Natl Acad Sci U S A (1975) 2.37
Regulation of pigment synthesis in mammalian cells, as studied by somatic hybridization. Proc Natl Acad Sci U S A (1966) 2.36
The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol (2000) 2.36
Isolation of different kinds of non-virus producing chick cells transformed by Schmidt-Ruppin strain (subgroup A) of Rous sarcoma virus. Jpn J Exp Med (1970) 2.35
Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol (1990) 2.34
Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum (2001) 2.28
Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats. Crit Care Med (2000) 2.25
v-maf, a viral oncogene that encodes a "leucine zipper" motif. Proc Natl Acad Sci U S A (1989) 2.24
Collective review of small carcinomas of the pancreas. Ann Surg (1986) 2.24
Hepatitis C virus antibody and hepatitis C virus replication in chronic hepatitis B patients. J Hepatol (1994) 2.23
Effects of moderate-intensity endurance and high-intensity intermittent training on anaerobic capacity and VO2max. Med Sci Sports Exerc (1996) 2.23
Construction and characterization of arginine-specific cysteine proteinase (Arg-gingipain)-deficient mutants of Porphyromonas gingivalis. Evidence for significant contribution of Arg-gingipain to virulence. J Biol Chem (1995) 2.23
Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res (1993) 2.22
Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci (2000) 2.21
Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science (1991) 2.18
Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med (1997) 2.17
The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J (2000) 2.17
Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus. Virology (1981) 2.16
Evolutionary molecular engineering by random elongation mutagenesis. Nat Biotechnol (1999) 2.15
Identity of hemolysins produced by Vibrio cholerae non-O1 and V. cholerae O1, biotype El Tor. Infect Immun (1986) 2.15
Conserved cysteine to serine mutation in tyrosinase is responsible for the classical albino mutation in laboratory mice. Nucleic Acids Res (1990) 2.13
Sequence variation in the 18S rRNA gene, a target for PCR-based malaria diagnosis, in Plasmodium ovale from southern Vietnam. J Clin Microbiol (1996) 2.12
Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene (2006) 2.10
Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis (2000) 2.07
Fetal Minamata disease. A neuropathological study of two cases of intrauterine intoxication by a methyl mercury compound. J Neuropathol Exp Neurol (1965) 2.05
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis (2010) 2.04
Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther (2014) 2.03
Cloning and characterization of mammalian 8-hydroxyguanine-specific DNA glycosylase/apurinic, apyrimidinic lyase, a functional mutM homologue. Cancer Res (1997) 2.02
Effect of iodixanol on renal function immediately after abdominal angiography. Clinical comparison with iomeprol and ioxaglate. Acta Radiol (1998) 2.01
Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet (1996) 2.00
Trehalose sensitivity in Drosophila correlates with mutations in and expression of the gustatory receptor gene Gr5a. Curr Biol (2001) 1.99
Free vascularized thin corticoperiosteal graft. Plast Reconstr Surg (1991) 1.98
Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med (1999) 1.95
A new avian erythroblastosis virus, AEV-H, carries erbB gene responsible for the induction of both erythroblastosis and sarcomas. Cell (1983) 1.95
Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci U S A (1990) 1.94
Evidence that a non-O1 Vibrio cholerae produces enterotoxin that is similar but not identical to cholera enterotoxin. Infect Immun (1983) 1.93
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice. Mol Med (1997) 1.92
Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsiveness in mice. J Immunol (2001) 1.91
Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome. J Virol (1985) 1.88
Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol (1986) 1.87
Plaque assay for some strains of avian leukosis virus. Virology (1972) 1.87
A cellular protein is immunologically crossreactive with and functionally homologous to the Fujinami sarcoma virus transforming protein. Cell (1982) 1.86
Semiquantitative grading of severity of mitral regurgitation by real-time two-dimensional Doppler flow imaging technique. J Am Coll Cardiol (1986) 1.86
Adjacent-segment morbidity after Graf ligamentoplasty compared with posterolateral lumbar fusion. J Neurosurg (2001) 1.86
Genome structure of avian sarcoma virus Y73 and unique sequence coding for polyprotein p90. J Virol (1981) 1.85
Dissociation of phagocytosis from stimulation of the oxidative metabolic burst in macrophages. J Exp Med (1984) 1.85
Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum (1999) 1.85
Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum (1995) 1.85
Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest (1995) 1.85
Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain (1999) 1.84
Characterization of a Rous sarcoma virus mutant defective in packaging its own genomic RNA: biological properties of mutant TK15 and mutant-induced transformants. J Virol (1984) 1.83
ATP-driven chromatin remodeling activity and histone acetyltransferases act sequentially during transactivation by RAR/RXR In vitro. Mol Cell (2000) 1.83